Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays

Radiation Research

Volumn 167, Issue 5, 2007, Pages 563-571

  Iizuka, Daisuke ^a   Inanami, Osamu ^a   Kashiwakura, Ikuo ^b   Kuwabara, Mikinori ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL XL; PROTEIN P53; PURVALANOL A; REGULATOR PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; 6 ((3 CHLORO)ANILINO) 2 (ISOPROPYL 2 HYDROXYETHYLAMINO) 9 ISOPROPYLPURINE; 6-((3-CHLORO)ANILINO)-2-(ISOPROPYL-2-HYDROXYETHYLAMINO)-9-ISOPROPYLPURINE; CELL CYCLE PROTEIN; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FRACTIONATION; CELL KILLING; CLONOGENESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; STOMACH TUMOR; TUMOR CELL; UPREGULATION; X IRRADIATION; CELL DIVISION; CELL LINE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; X RAY;

APOPTOSIS; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; G2 PHASE; HUMANS; NEOPLASMS; PURINES; UP-REGULATION; X-RAYS;

EID: 34249941557     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0622.1     Document Type: Article

References (27)

1. T. S. Lawrence, A. W. Blackstock and C. McGinn, The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin. Radiat. Oncol. 13, 13-21 (2003).
2. S. Tabata, M. Tanaka, Y. Endo, T. Obata, A. Matsuda and T. Sasaki, Anti-tumor mechanisms of 3′-ethynyluridine and 3′-ethynylcytidine as RNA synthesis inhibitors: Development and characterization of 3′-ethynyluridine-resistant cells. Cancer Lett. 116, 225-231 (1997).
3. O. Inanami, D. Iizuka, A. Iwahara, T. Yamamori, Y. Kon, T. Asanuma, A. Matsuda, I. Kashiwakura, K. Kitazato and M. Kuwabara, A novel anticancer ribonucleoside, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine, enhances radiation-induced cell death in tumor cells. Radiat. Res. 162, 635-645 (2004).
4. D. Iizuka, O. Inanami, A. Matsuda, I. Kashiwakura, T. Asanuma and M. Kuwabara, X irradiation induces the proapoptotic state independent of the loss of clonogenic ability in Chinese hamster V79 cells. Radiat. Res. 164, 36-44 (2005).
5. D. S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, P. C. Marchisio and D. C. Altieri, Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA 97, 13103-13107 (2000).
6. M. Mesri, N. R. Wall, J. Li, R. W. Kim and D. C. Altieri, Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108, 981-990 (2001).
7. N. R. Wall, D. S. O'Connor, J. Plescia, Y. Pommier and D. C. Altieri, Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 63, 230-235 (2003).
8. N. S. Gray, L. Wodicka, A. M. Thunnissen, T. C. Norman, S. Kwon, F. H. Espinoza, D. O. Morgan, G. Barnes, S. LeClerc and P. G. Schultz, Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
9. I. R. Hardcastle, B. T. Golding and R. J. Griffin, Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 42, 325-348 (2002).
10. D. S. O'Connor, N. R. Wall, A. C. Porter and D. C. Altieri, A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2, 43-54 (2002).
11. I. Kashiwakura, M. Murakami, O. Inanami, Y. Hayase, T. A. Takahashi, M. Kuwabara and Y. Takagi, Effects of amifostine on the proliferation and differentiation of megakaryocytic progenitor cells. Eur. J. Pharmacol. 437, 19-25 (2002).
12. D. Arion, L. Meijer, L. Brizuela and D. Beach, cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF. Cell 55, 371-378 (1988).
13. N. Villerbu, A. M. Gaben, G. Redeuilh and J. Mester, Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities. Int. J. Cancer 97, 761-769 (2002).
14. G. M. Cohen, Caspases: The executioners of apoptosis. Biochem. J. 326, 1-16 (1997).
15. E. C. Busby, D. F. Leistritz, R. T. Abraham, L. M. Karnitz and J. N. Sarkaria, The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60, 2108-2112 (2000).
16. 2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines. Br. J. Cancer 87, 352-358 (2002).
17. 2/M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53. Int. J. Cancer 96, 110-117 (2001).
18. J. N. Sarkaria, E. C. Busby, R. S. Tibbetts, P. Roos, Y. Taya, L. M. Karnitz and R. T. Abraham, Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375-4382 (1999).
19. 2/M block in murine T-lymphoma cells. Radiat. Res. 141, 235-243 (1995).
20. F. Essmann, I. H. Engels, G. Totzke, K. Schulze-Osthoff and R. U. Janicke, Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res. 64, 7065-7072 (2004).
21. J. Zhao, T. Tenev, L. M. Martins, J. Downward and N. R. Lemoine, The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113, 4363-4371 (2000).
22. E. H. Kim, S. U. Kim, D. Y. Shin and K. S. Choi, Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23, 446-456 (2004).
23. D. C. Altieri, The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7, 542-547 (2001).
24. C. W. Wright and C. S. Duckett, Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115, 2673-2678 (2005).
25. L. Yang, Z. Cao, H. Yan and W. C. Wood, Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res. 63, 6815-6824 (2003).
26. L, and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355-369 (2000).
27. L protein. Oncogene 24, 148-156 (2005).